ACS Publications. Most Trusted. Most Cited. Most Read
My Activity

Figure 1Loading Img

Predicting Circulating Human Metabolites: How Good Are We?

View Author Information
Department of Drug Disposition, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285
* To whom correspondence should be addressed. Tel: 317-276-0711. Fax: 317-433-6432. E-mail: [email protected]
Cite this: Chem. Res. Toxicol. 2009, 22, 2, 243–256
Publication Date (Web):January 12, 2009
Copyright © 2009 American Chemical Society

    Article Views





    Other access options


    Abstract Image

    The FDA issued a guidance on the safety testing of metabolites in February 2008, in which they stated that metabolites of concern are those that are detected at levels greater than 10% of the systemic exposure of the parent at steady state. This has presented many challenges in determining the circulating human metabolites at an early stage of development. The intention of this perspective is to address the question of how effective in vitro metabolism and early exploratory clinical data are in predicting the circulating metabolites from both a qualitative and a quantitative perspective. To this end, data were reviewed from 17 molecules in the Lilly portfolio for which there were in vitro data and a radiolabeled study in humans. Twelve example cases are presented in detail to demonstrate trends for when in vitro data adequately predicted in vivo (41%), when in vitro data underpredicted the circulating metabolites (35%), and when in vitro data overpredicted the circulating metabolites (24%). In addition, cases that present special challenges due to very low levels of the circulating parent or long half-lives of the parent and/or metabolites are presented. The trends indicate that the more complex the metabolism, the less likely the in vitro data were to predict the circulating metabolites. The in vitro data were also less predictive for N-glucuronidations and non-P450-mediated cleavage reactions. Although the in vitro data were better at predicting clearance pathways, the data set often failed to predict the quantity of metabolites, which is needed in consideration of whether or not a “disproportionate” metabolite may be circulating in human plasma.

    Read this article

    To access this article, please review the available access options below.

    Get instant access

    Purchase Access

    Read this article for 48 hours. Check out below using your ACS ID or as a guest.


    Access through Your Institution

    You may have access to this article through your institution.

    Your institution does not have access to this content. You can change your affiliated institution below.

    Cited By

    This article is cited by 95 publications.

    1. Keith Fraser, Dylan M. Bruckner, Jonathan S. Dordick. Advancing Predictive Hepatotoxicity at the Intersection of Experimental, in Silico, and Artificial Intelligence Technologies. Chemical Research in Toxicology 2018, 31 (6) , 412-430.
    2. Johanna Haglund, Magnus M. Halldin, Åsa Brunnström, Göran Eklund, Antti Kautiainen, Anna Sandholm, and Suzanne L. Iverson . Pragmatic Approaches to Determine the Exposures of Drug Metabolites in Preclinical and Clinical Subjects in the MIST Evaluation of the Clinical Development Phase. Chemical Research in Toxicology 2014, 27 (4) , 601-610.
    3. Natalia Penner, Lin Xu, and Chandra Prakash . Radiolabeled Absorption, Distribution, Metabolism, and Excretion Studies in Drug Development: Why, When, and How?. Chemical Research in Toxicology 2012, 25 (3) , 513-531.
    4. Hidetaka Kamimura, Shotaro Uehara, Nao Yoneda, Hiroshi Suemizu. Empirical scaling factor for predicting human pharmacokinetic profiles of disproportionate metabolites using the Css–MRTpo method and chimeric mice with humanised livers. Xenobiotica 2023, 53 (8-9) , 523-535.
    5. Debra Luffer-Atlas, R. Scott Obach, Dennis A. Smith. A MIST conception: what has been learned from twenty years of human metabolite safety assessment?. Medicinal Chemistry Research 2023, 32 (9) , 1933-1949.
    6. William L. Fitch, Steven Smith, Michael Saporito, Gregory Busse, Mingbao Zhang, Julie Ren, Michael E. Fitzsimmons, Ping Yi, Stephen English, Adam Carter, Thomas A. Baillie. Complex Metabolism of the Novel Neurosteroid, Ganaxolone, in Humans: A Unique Challenge for Metabolites in Safety Testing Assessment. Drug Metabolism and Disposition 2023, 51 (6) , 753-763.
    7. Simon G. Wong, Shuguang Ma. Design, conduct, and interpretation of human mass balance studies and strategies for assessing metabolites-in-safety testing (MIST) in drug development. 2023, 137-174.
    8. Chandra Prakash. Disproportionate drug metabolites: challenges and solutions. 2023, 223-238.
    9. Chaoyi Deng, Jin Liu, Wensheng Zhang. Structural Modification in Anesthetic Drug Development for Prodrugs and Soft Drugs. Frontiers in Pharmacology 2022, 13
    10. Daigo Asano, Syoya Hamaue, Hamim Zahir, Hideyuki Shiozawa, Yumi Nishiya, Takako Kimura, Miho Kazui, Naotoshi Yamamura, Marie Ikeguchi, Takahiro Shibayama, Shin-ichi Inoue, Tsuyoshi Shinozuka, Toshiyuki Watanabe, Chizuko Yahara, Nobuaki Watanabe, Kouichi Yoshinari. CYP2C8-Mediated Formation of a Human Disproportionate Metabolite of the Selective Na V 1.7 Inhibitor DS-1971a, a Mixed Cytochrome P450 and Aldehyde Oxidase Substrate. Drug Metabolism and Disposition 2022, 50 (3) , 235-242.
    11. Sonia Youhanna, Aurino M. Kemas, Lena Preiss, Yitian Zhou, Joanne X. Shen, Selgin D. Cakal, Francesco S. Paqualini, Sravan K. Goparaju, Reza Zandi Shafagh, Johan Ulrik Lind, Carl M. Sellgren, Volker M. Lauschke, . Organotypic and Microphysiological Human Tissue Models for Drug Discovery and Development—Current State-of-the-Art and Future Perspectives. Pharmacological Reviews 2022, 74 (1) , 141-206.
    12. , Antonio F Hernandez‐Jerez, Paulien Adriaanse, Annette Aldrich, Philippe Berny, Tamara Coja, Sabine Duquesne, Andreas Focks, Marina Marinovich, Maurice Millet, Olavi Pelkonen, Silvia Pieper, Aaldrik Tiktak, Christopher J Topping, Anneli Widenfalk, Martin Wilks, Gerrit Wolterink, Ursula Gundert‐Remy, Jochem Louisse, Serge Rudaz, Emanuela Testai, Alfonso Lostia, Jean‐Lou Dorne, Juan Manuel Parra Morte. Scientific Opinion of the Scientific Panel on Plant Protection Products and their Residues (PPR Panel) on testing and interpretation of comparative in vitro metabolism studies. EFSA Journal 2021, 19 (12)
    13. Daigo Asano, Takahiro Shibayama, Hideyuki Shiozawa, Shin-ichi Inoue, Tsuyoshi Shinozuka, Shinji Murata, Nobuaki Watanabe, Kouichi Yoshinari. Evaluation of species differences in the metabolism of the selective Na V 1.7 inhibitor DS-1971a, a mixed substrate of cytochrome P450 and aldehyde oxidase. Xenobiotica 2021, 51 (9) , 1060-1070.
    14. Jaydeep Yadav, Mehdi El Hassani, Jasleen Sodhi, Volker M. Lauschke, Jessica H. Hartman, Laura E. Russell. Recent developments in in vitro and in vivo models for improved translation of preclinical pharmacokinetics and pharmacodynamics data. Drug Metabolism Reviews 2021, 53 (2) , 207-233.
    15. Ruba S. Darweesh, Tamam El-Elimat, Aref Zayed, Tareq N. Khamis, Wahby M. Babaresh, Tawfiq Arafat, Ahmed H. Al Sharie. The effect of grape seed and green tea extracts on the pharmacokinetics of imatinib and its main metabolite, N-desmethyl imatinib, in rats. BMC Pharmacology and Toxicology 2020, 21 (1)
    16. Ruba S. Darweesh, Tareq N. Khamis, Tamam El-Elimat. The effect of cannabidiol on the pharmacokinetics of carbamazepine in rats. Naunyn-Schmiedeberg's Archives of Pharmacology 2020, 393 (10) , 1871-1886.
    17. Suguru Kato, Abhi Shah, Mihaela Plesescu, Yoshinari Miyata, Jayaprakasam Bolleddula, Swapan Chowdhury, Xiaochun Zhu. Prediction of Human Disproportionate and Biliary Excreted Metabolites Using Chimeric Mice with Humanized Liver. Drug Metabolism and Disposition 2020, 48 (10) , 934-943.
    18. Kimiyuki Shibuya, Toru Miura, Tadaaki Ohgiya, Kozo Omichi, Yoshihiko Tsunenari. Syntheses and pharmacokinetic evaluations of four metabolites of 2-(4-(2-((1H-benzo[d]imidazol-2-yl)thio)ethyl)piperazin-1-yl)-N-(6-methyl-2,4-bis-(methylthio)pyridin-3-yl)acetamide hydrochloride [K-604], an acyl-CoA:cholesterol O-acyltransferase-1 inhibitor. Bioorganic & Medicinal Chemistry 2020, 28 (11) , 115457.
    19. Yitian Zhou, Joanne X. Shen, Volker M. Lauschke. Comprehensive Evaluation of Organotypic and Microphysiological Liver Models for Prediction of Drug-Induced Liver Injury. Frontiers in Pharmacology 2019, 10
    20. Volker M. Lauschke, Reza Z. Shafagh, Delilah F. G. Hendriks, Magnus Ingelman‐Sundberg. 3D Primary Hepatocyte Culture Systems for Analyses of Liver Diseases, Drug Metabolism, and Toxicity: Emerging Culture Paradigms and Applications. Biotechnology Journal 2019, 14 (7)
    21. Yoko M. Ambrosini, Dana Borcherding, Anumantha Kanthasamy, Hyun Jung Kim, Auriel A. Willette, Albert Jergens, Karin Allenspach, Jonathan P. Mochel. The Gut-Brain Axis in Neurodegenerative Diseases and Relevance of the Canine Model: A Review. Frontiers in Aging Neuroscience 2019, 11
    22. Adeline N. Boettcher, Crystal L. Loving, Joan E. Cunnick, Christopher K. Tuggle. Development of Severe Combined Immunodeficient (SCID) Pig Models for Translational Cancer Modeling: Future Insights on How Humanized SCID Pigs Can Improve Preclinical Cancer Research. Frontiers in Oncology 2018, 8
    23. Richard D. Burton, Todd Hieronymus, Taysir Chamem, David Heim, Shelby Anderson, Xiaochun Zhu, J. Matthew Hutzler. Assessment of the Biotransformation of Low-Turnover Drugs in the H µ REL Human Hepatocyte Coculture Model. Drug Metabolism and Disposition 2018, 46 (11) , 1617-1625.
    24. Fallon K. Noto, Valeriya Adjan-Steffey, Min Tong, Kameswaran Ravichandran, Wei Zhang, Angela Arey, Christopher B. McClain, Eric Ostertag, Sahar Mazhar, Jaya Sangodkar, Analisa DiFeo, Jack Crawford, Goutham Narla, Tseten Y. Jamling. Sprague Dawley Rag2 -Null Rats Created from Engineered Spermatogonial Stem Cells Are Immunodeficient and Permissive to Human Xenografts. Molecular Cancer Therapeutics 2018, 17 (11) , 2481-2489.
    25. Nuggehally R. Srinivas. Pharmacology of Pimasertib, A Selective MEK1/2 Inhibitor. European Journal of Drug Metabolism and Pharmacokinetics 2018, 43 (4) , 373-382.
    26. Fan Yang, David Machalz, Sisi Wang, Zhengyi Li, Gerhard Wolber, Matthias Bureik. A common polymorphic variant of UGT 1A5 displays increased activity due to optimized cofactor binding. FEBS Letters 2018, 592 (11) , 1837-1846.
    27. Jian Zhou, Yong Ma. The Importance of Metabolite Pharmacokinetics Studies in Drug Development. International Journal of Pharmacokinetics 2018, 3 (1) , 5-9.
    28. Mercedes Barzi, Francis P. Pankowicz, Barry Zorman, Xing Liu, Xavier Legras, Diane Yang, Malgorzata Borowiak, Beatrice Bissig-Choisat, Pavel Sumazin, Feng Li, Karl-Dimiter Bissig. A novel humanized mouse lacking murine P450 oxidoreductase for studying human drug metabolism. Nature Communications 2017, 8 (1)
    29. Andrew TL Wotherspoon, Mitra Safavi-Naeini, Richard B Banati. Microdosing, Isotopic Labeling, Radiotracers and Metabolomics: Relevance in Drug Discovery, Development and Safety. Bioanalysis 2017, 9 (23) , 1913-1933.
    30. Debra Luffer-Atlas, Aisar Atrakchi. A decade of drug metabolite safety testing: industry and regulatory shared learning. Expert Opinion on Drug Metabolism & Toxicology 2017, 13 (9) , 897-900.
    31. Hoa Q. Nguyen, Jian Lin, Emi Kimoto, Ernesto Callegari, Susanna Tse, R. Scott Obach. Prediction of Losartan-Active Carboxylic Acid Metabolite Exposure Following Losartan Administration Using Static and Physiologically Based Pharmacokinetic Models. Journal of Pharmaceutical Sciences 2017, 106 (9) , 2758-2770.
    32. Hidetaka Kamimura, Satoshi Ito, Hiroyuki Chijiwa, Takeshi Okuzono, Tomohiro Ishiguro, Yosuke Yamamoto, Sho Nishinoaki, Shin-Ichi Ninomiya, Marina Mitsui, Amit S. Kalgutkar, Hiroshi Yamazaki, Hiroshi Suemizu. Simulation of human plasma concentration–time profiles of the partial glucokinase activator PF-04937319 and its disproportionate N-demethylated metabolite using humanized chimeric mice and semi-physiological pharmacokinetic modeling. Xenobiotica 2017, 47 (5) , 382-393.
    33. T. Hartung. A Comprehensive Overview of the Current Status and Application of Predictive ADMET: Introduction and Overview. 2017, 150-155.
    35. R. Scott Obach, Amit S. Kalgutkar, Deepak K. Dalvie. IN VITRO METHODS FOR EVALUATION OF DRUG METABOLISM. 2016, 87-110.
    36. Lars Weidolf, Ian D. Wilson. UNDERSTANDING DRUG METABOLISM IN HUMANS. 2016, 141-176.
    37. I. J. Martin, S. E. Hill, J. A. Baker, S. V. Deshmukh, E. F. Mulrooney. A Pharmacokinetic Modeling Approach to Predict the Contribution of Active Metabolites to Human Efficacious Dose. Drug Metabolism and Disposition 2016, 44 (8) , 1435-1440.
    38. Hidetaka Kamimura, Satoshi Ito. Assessment of chimeric mice with humanized livers in new drug development: generation of pharmacokinetics, metabolism and toxicity data for selecting the final candidate compound. Xenobiotica 2016, 46 (6) , 557-569.
    39. H. Q. Nguyen, E. Kimoto, E. Callegari, R. S. Obach. Mechanistic Modeling to Predict Midazolam Metabolite Exposure from In Vitro Data. Drug Metabolism and Disposition 2016, 44 (5) , 781-791.
    40. J. Iegre, M. A. Hayes, R. A. Thompson, L. Weidolf, E. M. Isin. Database Extraction of Metabolite Information of Drug Candidates: Analysis of 27 AstraZeneca Compounds with Human Absorption, Distribution, Metabolism, and Excretion Data. Drug Metabolism and Disposition 2016, 44 (5) , 732-740.
    41. S.-E. W. Huskey, C.-q. Zhu, M. M. Lin, R. R. Forseth, H. Gu, O. Simon, F. K. Eggimann, M. Kittelmann, A. Luneau, A. Vargas, H. Li, L. Wang, H. J. Einolf, J. Zhang, S. Favara, H. He, J. B. Mangold. Identification of Three Novel Ring Expansion Metabolites of KAE609, a New Spiroindolone Agent for the Treatment of Malaria, in Rats, Dogs, and Humans. Drug Metabolism and Disposition 2016, 44 (5) , 653-664.
    42. Nico Scheer, Ian D. Wilson. A comparison between genetically humanized and chimeric liver humanized mouse models for studies in drug metabolism and toxicity. Drug Discovery Today 2016, 21 (2) , 250-263.
    43. Dan Xu, Gary Peltz. Can Humanized Mice Predict Drug “Behavior” in Humans?. Annual Review of Pharmacology and Toxicology 2016, 56 (1) , 323-338.
    44. J. Matthew Hutzler, Barbara J. Ring, Shelby R. Anderson. Low-Turnover Drug Molecules: A Current Challenge for Drug Metabolism Scientists. Drug Metabolism and Disposition 2015, 43 (12) , 1917-1928.
    45. Thomas A. Baillie. Chemically Reactive Versus Stable Drug Metabolites: Role in Adverse Drug Reactions. 2015, 202-226.
    46. Francisco Altamirano, Zhao V. Wang, Joseph A. Hill. Cardioprotection in ischaemia–reperfusion injury: novel mechanisms and clinical translation. The Journal of Physiology 2015, 593 (17) , 3773-3788.
    47. Kota Kato, Masato Ohbuchi, Satoko Hamamura, Hiroki Ohshita, Yasuhiro Kazuki, Mitsuo Oshimura, Koya Sato, Naoyuki Nakada, Akio Kawamura, Takashi Usui, Hidetaka Kamimura, Chise Tateno. Development of Murine Cyp3a Knockout Chimeric Mice with Humanized Liver. Drug Metabolism and Disposition 2015, 43 (8) , 1208-1217.
    48. Ari Tolonen, Olavi Pelkonen. Analytical challenges for conducting rapid metabolism characterization for QIVIVE. Toxicology 2015, 332 , 20-29.
    49. Dan Xu, Manhong Wu, Sachiko Nishimura, Toshihiko Nishimura, Sara A. Michie, Ming Zheng, Zicheng Yang, Alexander John Yates, Jeffrey S. Day, Kathleen M. Hillgren, Saori Takedai Takeda, Yuan Guan, Yingying Guo, Gary Peltz. Chimeric TK-NOG Mice: A Predictive Model for Cholestatic Human Liver Toxicity. Journal of Pharmacology and Experimental Therapeutics 2015, 352 (2) , 274-280.
    50. Thomas J. Bateman, Vijay G.B. Reddy, Masakazu Kakuni, Yoshio Morikawa, Sanjeev Kumar. Application of Chimeric Mice with Humanized Liver for Study of Human-Specific Drug Metabolism. Drug Metabolism and Disposition 2014, 42 (6) , 1055-1065.
    51. T. Eric Ballard, Christine C. Orozco, R. Scott Obach. Generation of Major Human Excretory and Circulating Drug Metabolites Using a Hepatocyte Relay Method. Drug Metabolism and Disposition 2014, 42 (5) , 899-902.
    52. Yoshiyuki Igawa, Tomomichi Fujitani, Bharti Shah, Charles Oo, Yasushi Kanai. In vitro and in vivo metabolism of a novel chymase inhibitor, SUN13834, and the predictability of human metabolism using mice with humanized liver. Xenobiotica 2014, 44 (2) , 154-163.
    53. John R. Foster, Garry Lund, Svetlana Sapelnikova, D. Lorne Tyrrell, Norman M. Kneteman. Chimeric rodents with humanized liver: bridging the preclinical/clinical trial gap in ADME/toxicity studies. Xenobiotica 2014, 44 (2) , 109-122.
    54. Natalia A. Penner, Joanna Zgoda‐Pols, Chandra Prakash. Early Assessment of Exposure of Drug Metabolites in Humans Using Mass Spectrometry. 2014, 1-29.
    55. Takako Ohkura, Kunihiro Ohta, Takuya Nagao, Kumiko Kusumoto, Akiko Koeda, Tadayoshi Ueda, Tomoko Jomura, Takeshi Ikeya, Emiko Ozeki, Kazuki Wada, Kazushi Naitoh, Yukiko Inoue, Naoki Takahashi, Hisakazu Iwai, Hiroshi Arakawa, Takuo Ogihara. Evaluation of Human Hepatocytes Cultured by Three-dimensional Spheroid Systems for Drug Metabolism. Drug Metabolism and Pharmacokinetics 2014, 29 (5) , 373-378.
    56. Ragu Ramanathan, Dil M. Ramanathan. Metabolites in Safety Testing. 2013, 71-82.
    57. Gary Peltz. Can ‘humanized’ mice improve drug development in the 21st century?. Trends in Pharmacological Sciences 2013, 34 (5) , 255-260.
    58. Toshihiko Nishimura, Yajing Hu, Manhong Wu, Edward Pham, Hiroshi Suemizu, Menashe Elazar, Michael Liu, Ramazan Idilman, Cihan Yurdaydin, Peter Angus, Catherine Stedman, Brian Murphy, Jeffrey Glenn, Masato Nakamura, Tatsuji Nomura, Yuan Chen, Ming Zheng, William L. Fitch, Gary Peltz. Using Chimeric Mice with Humanized Livers to Predict Human Drug Metabolism and a Drug-Drug Interaction. Journal of Pharmacology and Experimental Therapeutics 2013, 344 (2) , 388-396.
    59. David S Wagner, Jill L Pirhalla, Gary D Bowers. Metabolite Structure Analysis by High-Resolution MS: Supporting Drug-Development Studies. Bioanalysis 2013, 5 (4) , 463-479.
    60. P Ballard, P Brassil, K H Bui, H Dolgos, C Petersson, A Tunek, P J H Webborn. Metabolism and pharmacokinetic optimization strategies in drug discovery. 2013, 135-155.
    61. Seigo Sanoh, Aya Horiguchi, Kazumi Sugihara, Yaichiro Kotake, Yoshitaka Tayama, Naoto Uramaru, Hiroki Ohshita, Chise Tateno, Toru Horie, Shigeyuki Kitamura, Shigeru Ohta. Predictability of Metabolism of Ibuprofen and Naproxen Using Chimeric Mice with Human Hepatocytes. Drug Metabolism and Disposition 2012, 40 (12) , 2267-2272.
    62. Kristin Samuelsson, Kathryn Pickup, Sunil Sarda, John G. Swales, Yoshio Morikawa, Timothy Schulz-Utermoehl, Michael Hutchison, Ian D. Wilson. Pharmacokinetics and metabolism of midazolam in chimeric mice with humanised livers. Xenobiotica 2012, 42 (11) , 1128-1137.
    63. Debra Luffer-Atlas. The early estimation of circulating drug metabolites in humans. Expert Opinion on Drug Metabolism & Toxicology 2012, 8 (8) , 985-997.
    64. Peter Ballard, Patrick Brassil, Khanh H. Bui, Hugues Dolgos, Carl Petersson, Anders Tunek, Peter J. H. Webborn. The right compound in the right assay at the right time: an integrated discovery DMPK strategy. Drug Metabolism Reviews 2012, 44 (3) , 224-252.
    65. Timothy Schulz-Utermoehl, Sunil Sarda, John R. Foster, Matt Jacobsen, J. Gerry Kenna, Yoshio Morikawa, Juuso Salmu, Gerhard Gross, Ian D. Wilson. Evaluation of the pharmacokinetics, biotransformation and hepatic transporter effects of troglitazone in mice with humanized livers. Xenobiotica 2012, 42 (6) , 503-517.
    66. Michael D. Coleman, Louis L. Radulovic. Clinical Aspects of Drug Biotransformation: An OverviewDedicated to the memory of Mark J. Winn, Ph.D.,1960–1993. 2012, 1-50.
    67. Robert J. Greene, John A. Davis, Raju Subramanian, Molly R. Deane, Maurice G. Emery, J. Greg Slatter. Regiospecific and Stereospecific Triangulation of the Structures of Metabolites Formed by Sequential Metabolism at Multiple Prochiral Centers. Drug Metabolism and Disposition 2012, 40 (5) , 928-942.
    68. Graham Lappin, Mark Seymour, Gerhard Gross, Martin J⊘rgensen, Morten Kall, Lisbet Kværn⊘. Meeting The Mist Regulations: Human Metabolism in Phase I Using Ams And A Tiered Bioanalytical Approach. Bioanalysis 2012, 4 (4) , 407-416.
    69. Thomas A. Baillie. Drug Metabolism in Drug Safety Evaluation. 2012, 1-24.
    70. Raju Subramanian, J. Greg Slatter. Safety Testing of Drug Metabolites: A Practical Approach for the Implementation of the MIST Guidance in PKDM. 2012, 1-17.
    71. Shelby Anderson, Debra Luffer‐Atlas, Mary Pat Knadler. Predicting Human Biotransformation Pathways. 2012, 1-27.
    72. Justin D. Lutz, Nina Isoherranen. Prediction of Relative In Vivo Metabolite Exposure from In Vitro Data Using Two Model Drugs: Dextromethorphan and Omeprazole. Drug Metabolism and Disposition 2012, 40 (1) , 159-168.
    73. N. H. Schebb, B. Franze, R. Maul, A. Ranganathan, B. D. Hammock. In Vitro Glucuronidation of the Antibacterial Triclocarban and Its Oxidative Metabolites. Drug Metabolism and Disposition 2012, 40 (1) , 25-31.
    74. R. Scott Obach, Angus N. Nedderman, Dennis A. Smith. Radiolabelled mass-balance excretion and metabolism studies in laboratory animals: are they still necessary?. Xenobiotica 2012, 42 (1) , 46-56.
    75. Angus N.R. Nedderman, Gordon J. Dear, Stephanie North, R. Scott Obach, David Higton. From definition to implementation: a cross-industry perspective of past, current and future MIST strategies. Xenobiotica 2011, 41 (8) , 605-622.
    76. Ronald E. White. Progression of Drug Metabolism. 2011, 1-12.
    77. Takashi Izumi. Assessment of Drug Metabolites. Drug Metabolism and Pharmacokinetics 2011, 26 (2) , 121-122.
    78. Baskar Nammalwar, Richard A. Bunce, Doris M. Benbrook, Tao Lu, Hui-Fang Li, Ya-Dong Chen, K. Darrell Berlin. Synthesis of N -[3,4-Dihydro-4-(acetoxymethyl)-2,2,4-trimethyl-2 H -1-benzothiopyran-6-yl]- N ′-(4-nitrophenyl)thiourea and N -[3,4-dihydro-4-(hydroxymethyl)-2,2,4-trimethyl-2 H -1-benzothiopyran-6-yl]- N ′-(4-nitrophenyl)thiourea, a Major Metabolite of N -(3,4-Dihydro-2,2,4,4-tetramethyl-2 H -1-benzothiopyran-6-YL)- N ′-(4-nitrophenyl)thiourea. Phosphorus, Sulfur, and Silicon and the Related Elements 2010, 186 (1) , 189-204.
    79. J. Greg Slatter. Safety Testing of Drug Metabolites: Mist Guidance Impact on the Practice of Industrial Drug Metabolism. 2010, 295-312.
    80. Wendy WeiWei Wang, Salman R. Khetani, Stacy Krzyzewski, David B. Duignan, R. Scott Obach. Assessment of a Micropatterned Hepatocyte Coculture System to Generate Major Human Excretory and Circulating Drug Metabolites. Drug Metabolism and Disposition 2010, 38 (10) , 1900-1905.
    81. Justin D Lutz, Yasushi Fujioka, Nina Isoherranen. Rationalization and prediction of in vivo metabolite exposures: the role of metabolite kinetics, clearance predictions and in vitro parameters. Expert Opinion on Drug Metabolism & Toxicology 2010, 6 (9) , 1095-1109.
    82. Ping Yi, Debra Luffer-Atlas. A Radiocalibration Method with Pseudo Internal Standard to Estimate Circulating Metabolite Concentrations. Bioanalysis 2010, 2 (7) , 1195-1210.
    83. Shelby Anderson, Mary Pat Knadler, Debra Luffer-Atlas. Overview of Metabolite Safety Testing from an Industry Perspective. Bioanalysis 2010, 2 (7) , 1249-1261.
    84. Andy Zöllner, Daniela Buchheit, Markus R Meyer, Hans H Maurer, Frank T Peters, Matthias Bureik. Production of Human Phase 1 and 2 Metabolites by Whole-Cell Biotransformation with Recombinant Microbes. Bioanalysis 2010, 2 (7) , 1277-1290.
    85. Ragu Ramanathan, Jonathan L Josephs, Mohammed Jemal, Mark Arnold, W Griffith Humphreys. Novel MS Solutions Inspired by MIST. Bioanalysis 2010, 2 (7) , 1291-1313.
    86. Graham Lappin, Mark Seymour. Addressing Metabolite Safety During First-In-Man Studies Using 14 C-Labeled Drug and Accelerator Mass Spectrometry. Bioanalysis 2010, 2 (7) , 1315-1324.
    87. C. D. Markert, M. P. Meaney, K. A. Voelker, R. W. Grange, H. W. Dalley, J. K. Cann, M. Ahmed, B. Bishwokarma, S. J. Walker, S. X. Yu, M. Brown, M. W. Lawlor, A. H. Beggs, M. K. Childers. Functional muscle analysis of the Tcap knockout mouse. Human Molecular Genetics 2010, 19 (11) , 2268-2283.
    88. C B Frederick, R S Obach. Metabolites in Safety Testing: “MIST” for the Clinical Pharmacologist. Clinical Pharmacology & Therapeutics 2010, 87 (3) , 345-350.
    89. Stephen R Dueker, Peter N Lohstroh, Jason A Giacomo, Le T Vuong, Bradly D Keck, John S Vogel. Early Human ADME Using Microdoses and Microtracers: Bioanalytical Considerations. Bioanalysis 2010, 2 (3) , 441-454.
    90. Hidetaka Kamimura, Naoyuki Nakada, Katsuhiro Suzuki, Ayako Mera, Kinya Souda, Yuichi Murakami, Kohichiro Tanaka, Takafumi Iwatsubo, Akio Kawamura, Takashi Usui. Assessment of Chimeric Mice with Humanized Liver as a Tool for Predicting Circulating Human Metabolites. Drug Metabolism and Pharmacokinetics 2010, 25 (3) , 223-235.
    91. Akihiro INANO. . Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 2010, 41 (4) , 121S-122S.
    92. Ragu Ramanathan, S Çömezoglu, W Humphreys. Metabolite Identification Strategies and Procedures. 2009, 127-203.
    93. Gerhard Gross, Ian Wilson. Issues in the Safety Testing of Metabolites. Future Medicinal Chemistry 2009, 1 (8) , 1381-1390.
    94. Olavi Pelkonen, Ari Tolonen, Timo Korjamo, Miia Turpeinen, Hannu Raunio. From Known Knowns to Known Unknowns: Predicting in Vivo Drug Metabolites. Bioanalysis 2009, 1 (2) , 393-414.
    95. Thomas N. Thompson. Chapter 22 Safety Testing of Drug Metabolites. 2009, 459-474.

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    You’ve supercharged your research process with ACS and Mendeley!

    STEP 1:
    Click to create an ACS ID

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Your Mendeley pairing has expired. Please reconnect